采用CLSI M27 - A3肉汤微量稀释法对新生隐球菌-格特隐球菌复合种的异氟康唑MIC分布及流行病学截断值进行多中心研究。
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.
作者信息
Espinel-Ingroff A, Chowdhary A, Gonzalez G M, Guinea J, Hagen F, Meis J F, Thompson G R, Turnidge J
机构信息
VCU Medical Center, Richmond, Virginia, USA
Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.
出版信息
Antimicrob Agents Chemother. 2015 Jan;59(1):666-8. doi: 10.1128/AAC.04055-14. Epub 2014 Oct 13.
Abstract
Epidemiological cutoff values (ECVs) of isavuconazole are not available for Cryptococcus spp. The isavuconazole ECVs based on wild-type (WT) MIC distributions for 438 Cryptococcus neoformans nongenotyped isolates, 870 isolates of genotype VNI, and 406 Cryptococcus gattii isolates from six laboratories and different geographical areas were 0.06, 0.12, and 0.25 μg/ml, respectively. These ECVs may aid in detecting non-WT isolates with reduced susceptibilities to isavuconazole.
摘要
对于隐球菌属，目前尚无艾沙康唑的流行病学临界值（ECV）。基于来自六个实验室和不同地理区域的438株非基因分型新生隐球菌分离株、870株VNI基因型分离株以及406株加氏隐球菌分离株的野生型（WT）最低抑菌浓度（MIC）分布，艾沙康唑的ECV分别为0.06、0.12和0.25μg/ml。这些ECV可能有助于检测对艾沙康唑敏感性降低的非WT分离株。
相似文献
1
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.
Antimicrob Agents Chemother. 2015 Jan;59(1):666-8. doi: 10.1128/AAC.04055-14. Epub 2014 Oct 13.
2
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Antimicrob Agents Chemother. 2012 Nov;56(11):5898-906. doi: 10.1128/AAC.01115-12. Epub 2012 Sep 4.
3
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.
Antimicrob Agents Chemother. 2012 Jun;56(6):3107-13. doi: 10.1128/AAC.06252-11. Epub 2012 Mar 5.
4
Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Med Mycol. 2019 Oct 1;57(7):864-873. doi: 10.1093/mmy/myy150.
5
Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Mycoses. 2016 Sep;59(9):576-84. doi: 10.1111/myc.12507. Epub 2016 Apr 8.
6
Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.
Antimicrob Agents Chemother. 2008 Aug;52(8):2959-61. doi: 10.1128/AAC.00646-08. Epub 2008 Jun 16.
7
In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
Mycoses. 2015 May;58(5):273-9. doi: 10.1111/myc.12310. Epub 2015 Mar 10.
8
Molecular epidemiology and antifungal susceptibility profiles of clinical species complex.
J Med Microbiol. 2020 Jan;69(1):72-81. doi: 10.1099/jmm.0.001101.
9
Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.
Med Mycol. 2012 Apr;50(3):328-32. doi: 10.3109/13693786.2011.602126. Epub 2011 Aug 23.
10
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.
Antimicrob Agents Chemother. 2013 Aug;57(8):3823-8. doi: 10.1128/AAC.00636-13. Epub 2013 May 28.
引用本文的文献
1
Clinical and Molecular Characterization of Feline Sporotrichosis in the Brazilian Amazon: PCR-Based Identification of .
Animals (Basel). 2025 Aug 7;15(15):2318. doi: 10.3390/ani15152318.
2
Efficacy and safety of isavuconazole versus voriconazole for the treatment of invasive fungal infections: a meta-analysis with trial sequential analysis.
BMC Infect Dis. 2025 Feb 18;25(1):230. doi: 10.1186/s12879-025-10627-w.
3
Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List.
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myae043.
4
Exposure of to Seven Commonly Used Agricultural Azole Fungicides Induces Resistance to Fluconazole as Well as Cross-Resistance to Voriconazole, Posaconazole, Itraconazole and Isavuconazole.
Pathogens. 2023 Apr 29;12(5):662. doi: 10.3390/pathogens12050662.
5
False-negative cerebral spinal fluid cryptococcal antigen lateral flow assay due to postzone phenomenon in a patient with disseminated cryptococcal disease: a case report.
J Int Med Res. 2023 Mar;51(3):3000605231156767. doi: 10.1177/03000605231156767.
6
New Perspectives on Antimicrobial Agents: Isavuconazole.
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0017722. doi: 10.1128/aac.00177-22. Epub 2022 Aug 15.
7
Pharmacokinetics of isavuconazole in healthy cats after oral and intravenous administration.
J Vet Intern Med. 2022 Jul;36(4):1422-1429. doi: 10.1111/jvim.16452. Epub 2022 May 26.
8
Prevalence, Genetic Structure, and Antifungal Susceptibility of the Species Complex Strains Collected from the Arboreal Niche in Poland.
Pathogens. 2021 Dec 22;11(1):8. doi: 10.3390/pathogens11010008.
9
Risk Factors for Cryptococcal Meningitis Recurrence in Human Immunodeficiency Virus (HIV)-Infected Patients in a Large Chinese Acquired Immune Deficiency Syndrome (AIDS) Treatment Center.
Med Sci Monit. 2021 Dec 15;27:e933688. doi: 10.12659/MSM.933688.
10
Antifungal Susceptibility Profiles of var. and Clinical Isolates in Guangxi, Southern China.
Front Microbiol. 2021 Aug 10;12:708280. doi: 10.3389/fmicb.2021.708280. eCollection 2021.
本文引用的文献
1
Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.
Antimicrob Agents Chemother. 2014;58(4):2006-12. doi: 10.1128/AAC.02615-13. Epub 2014 Jan 13.
2
In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.
J Clin Microbiol. 2013 Aug;51(8):2608-16. doi: 10.1128/JCM.00863-13. Epub 2013 Jun 5.
3
Autochthonous and dormant Cryptococcus gattii infections in Europe.
Emerg Infect Dis. 2012 Oct;18(10):1618-24. doi: 10.3201/eid1810.120068.
4
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Antimicrob Agents Chemother. 2012 Nov;56(11):5898-906. doi: 10.1128/AAC.01115-12. Epub 2012 Sep 4.
5
Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population.
J Clin Microbiol. 2012 Jun;50(6):1918-26. doi: 10.1128/JCM.06750-11. Epub 2012 Mar 21.
6
Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen.
Clin Infect Dis. 2011 Dec;53(12):1188-95. doi: 10.1093/cid/cir723. Epub 2011 Oct 19.
7
A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients.
PLoS Pathog. 2011 Sep;7(9):e1002205. doi: 10.1371/journal.ppat.1002205. Epub 2011 Sep 1.
8
In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
J Med Microbiol. 2011 Jul;60(Pt 7):961-967. doi: 10.1099/jmm.0.029025-0. Epub 2011 Mar 10.
9
In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates.
Antimicrob Agents Chemother. 2010 Dec;54(12):5139-45. doi: 10.1128/AAC.00746-10. Epub 2010 Sep 20.
10
Mixed infections and In Vivo evolution in the human fungal pathogen Cryptococcus neoformans.
mBio. 2010 May 18;1(1):e00091-10. doi: 10.1128/mBio.00091-10.
Zotero 插件